Chronic Pain Clinical Trial
Official title:
The UPGRADE Study: Real World Outcomes® of Differential Target Multiplexed (DTM-SCS®) Stimulation in Existing and New Medtronic Implants
NCT number | NCT04725838 |
Other study ID # | UPGRADE |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 29, 2021 |
Est. completion date | January 29, 2025 |
The UPGRADE registry will capture long-term, real-world outcomes to understand the effect of Differential Target Multiplexed (DTM®) programming in the Spinal Cord Stimulation (SCS) implanted population on the management of chronic pain, primarily on its use for trunk and/or limb pain. The clinical study is sponsored by Celéri Health and is funded through a financial grant from Medtronic's External Research Program. The registry study will be conducted across approximately 25 centers in the United States with up to 600 participants enrolled.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | January 29, 2025 |
Est. primary completion date | January 29, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Participant must provide written informed consent prior to any clinical study-related procedure. 2. Participant is at least 18 years (or the minimum age required by local law to consent for participation in a clinical investigation) or older at the time of enrollment. 3. Participant has a permanent Medtronic Intellis™ neurostimulation system implanted or is planning to be implanted with a Medtronic Intellis™ or Vanta™ neurostimulation system. 4. Participant has access to an iPhone or Android capable device and/or computer with regular internet access for the purposes of electronically completing web-based participant self-reported questionnaires via SMS text or email. Exclusion Criteria: 1. Participant is unable to provide written informed consent or to comply with study-related requirements, procedures, and visits. 2. Participant is a profound responder for all pain areas to existing neurostimulation therapy (=80% reported relief). 3. Participant is enrolled, or intends to participate, in a clinical drug and/or device study (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) which could confound the results of this trial as determined by the investigator. 4. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements. 5. Participant is pregnant or nursing. |
Country | Name | City | State |
---|---|---|---|
United States | Neuroversion | Anchorage | Alaska |
United States | Millennium Pain Center (National Spine and Pain Centers - Bloomington, IL) | Bloomington | Illinois |
United States | Florida Pain Medicine - Brandon | Brandon | Florida |
United States | NuVation Pain Group - Buena Park | Buena Park | California |
United States | Carolinas Research Institute - Mallard Creek | Charlotte | North Carolina |
United States | Jax Spine & Pain Centers - Fleming Island | Fleming Island | Florida |
United States | North Texas Orthopedics & Spine Center- Keller/Alliance | Fort Worth | Texas |
United States | North Texas Orthopedics & Spine Center - Grapevine | Grapevine | Texas |
United States | Comprehensive and Interventional Pain Management | Henderson | Nevada |
United States | Premier Pain Treatment Institute - Hillsboro | Hillsboro | Ohio |
United States | Carolinas Research Institute - Huntersville | Huntersville | North Carolina |
United States | Jax Spine & Pain Centers - Jacksonville | Jacksonville | Florida |
United States | Jax Spine & Pain Centers - UF North | Jacksonville | Florida |
United States | NuVation Pain Group - Los Angeles | Los Angeles | California |
United States | Premier Pain Treatment Institute - Loveland | Loveland | Ohio |
United States | Premier Pain Treatment Institute - Mt. Orab | Mount Orab | Ohio |
United States | Oklahoma Pain Physicians - Norman | Norman | Oklahoma |
United States | Oklahoma Pain Physicians - Oklahoma City | Oklahoma City | Oklahoma |
United States | Spine and Sports Specialty Medical Group | Orange | California |
United States | Desert Sky Spine & Sports Medicine | Oro Valley | Arizona |
United States | National Spine and Pain Centers - National Harbor (Oxon Hill) | Oxon Hill | Maryland |
United States | National Spine and Pain Centers - Pikesville, MD | Pikesville | Maryland |
United States | Oklahoma Pain Physicians - Purcell | Purcell | Oklahoma |
United States | Florida Spine & Pain Specialists | Riverview | Florida |
United States | Spine & Nerve Diagnostic Center - Roseville | Roseville | California |
United States | Jax Spine & Pain Centers -St. Augustine | Saint Augustine | Florida |
United States | Desert Sky Spine & Sports Medicine | Sierra Vista | Arizona |
United States | Northwest Pain Care | Spokane | Washington |
United States | Precision Spine Care | Tyler | Texas |
United States | National Spine and Pain Centers - The Pain Management Center - Voorhees | Voorhees | New Jersey |
United States | Centurion Spine & Pain Centers (Jax Spine) | Waycross | Georgia |
United States | Florida Pain Medicine - Wesley Chapel | Wesley Chapel | Florida |
United States | Valley Pain Consultants | Winchester | Virginia |
United States | National Spine and Pain Centers - Winter Park, FL | Winter Park | Florida |
Lead Sponsor | Collaborator |
---|---|
Celéri Health, Inc. | Medtronic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the Pain Impact Score as measured by the PROMIS-29 before and after introduction of Differential Target Multiplexed (DTM®) stimulation programming in a real-world population. | 24 months | ||
Secondary | To characterize the responder rate for pain by pain area per Percent Pain Relief for DTM-SCS® compared to participant baseline treatment. | 24 months | ||
Secondary | To characterize the responder rate for pain by pain area per Numeric Rating Scale for DTM-SCS® compared to participant baseline treatment. | 24 months | ||
Secondary | To evaluate the longitudinal characterization of objective posture and activity measures. | Time spent in each activity/position (Intellis™ device data) | 24 months | |
Secondary | To characterize Patient Global Impression of Change (PGIC) with neurostimulation. | 24 months | ||
Secondary | To evaluate the performance of the DTM® pre-programming questionnaire in predicting outcome of DTM-SCS® programming. | 24 months | ||
Secondary | To characterize the neuropathic pain quality using PROMIS-Neuropathic Pain Quality (PROMIS-PQ-Neuro) before and after treatment. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|